Comparative Pharmacology
Head-to-head clinical analysis: CHYMODIACTIN versus TRYPTYR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHYMODIACTIN versus TRYPTYR.
CHYMODIACTIN vs TRYPTYR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chymodiacrin is a proteolytic enzyme that cleaves peptide bonds in proteoglycans, specifically targeting chondroitin sulfate and keratan sulfate in the intervertebral disc nucleus pulposus. This degradation reduces intradiscal pressure, alleviating nerve root compression in herniated lumbar discs.
TRYPTYR is a prodrug of tryptamine, acting as a serotonin (5-HT) receptor agonist. It enhances serotonergic neurotransmission by binding to 5-HT2A, 5-HT2C, and 5-HT1A receptors, leading to altered perception and mood. It also inhibits the reuptake of serotonin, norepinephrine, and dopamine.
2000-3000 IU intradiscal injection as a single dose.
100 mg orally every 6 hours for 14 days; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 45 minutes; clinically, this rapid clearance limits systemic accumulation.
Terminal elimination half-life is 18-24 hours in healthy adults, allowing once-daily dosing. Half-life may be prolonged in renal impairment (up to 40 hours in CrCl <30 mL/min).
Renal: 30% as intact drug; fecal: 70% as metabolites; biliary excretion is negligible.
TRYPTYR is primarily eliminated via renal excretion as unchanged drug (60-70%) and hepatic metabolism (30-40%), with metabolites excreted in bile/feces (10-15% total).
Category C
Category C
Proteolytic Enzyme
Proteolytic Enzyme